Who Exports Lansoprazole from India — 316 Suppliers Behind a $290.2M Market
India's lansoprazole export market is supplied by 316 active exporters who collectively shipped $290.2M across 4,867 shipments. SANDOZ PRIVATE LIMITED leads with a 54.8% market share, followed by MYLAN LABORATORIES LIMITED and PAR FORMULATIONS PRIVATE LIMITED. The top 5 suppliers together control 79.8% of total export value, reflecting a concentrated market structure.
Top Lansoprazole Exporters from India — Ranked by Export Value
SANDOZ PRIVATE LIMITED is the leading lansoprazole exporter from India, holding a 54.8% share of the $290.2M market across 4,867 shipments from 316 exporters. The top 5 suppliers — SANDOZ PRIVATE LIMITED, MYLAN LABORATORIES LIMITED, PAR FORMULATIONS PRIVATE LIMITED, LINCOLN PHARMACEUTICALS LTD, CIPLA LIMITED — collectively control 79.8% of total export value, indicating a highly concentrated market. Individual shares are: SANDOZ PRIVATE LIMITED (54.8%), MYLAN LABORATORIES LIMITED (9.1%), PAR FORMULATIONS PRIVATE LIMITED (6.8%), LINCOLN PHARMACEUTICALS LTD (5.1%), CIPLA LIMITED (3.9%).
Top Lansoprazole Exporters from India
Ranked by export value · 316 active suppliers · Indian Customs (DGFT) data
| # | Supplier & Formulations | Value | Ctry. | Share |
|---|---|---|---|---|
| 1 | SANDOZ PRIVATE LIMITED LANSOPRAZOLE HGC 30MG IN91 SH MS MATERIAL NO. - 42021949LANSOPRAZOLE HGC 30MG IN91 SH MS MATERIAMATERIAL NO. - 42021949, LANSOPRAZOLE HG | $159.0M | 2 | 54.8% |
| 2 | MYLAN LABORATORIES LIMITED LANSOPRAZOLE HGC 30MG IN91 SH MS MATERIAL NO. - 42021949LANSOPRAZOLE DR OD TAB 30 MG - 10 X 10LANSOPRAZOLE MYLAN 30 MG 28BL | $26.5M | 9 | 9.1% |
| 3 | PAR FORMULATIONS PRIVATE LIMITED LANSOPRAZOLE DR OD TAB 30 MG - 10 X 10LANSOPRAZOLE DR OD TAB 15 MG - 10 X 10TBS | $19.8M | 1 | 6.8% |
| 4 | LINCOLN PHARMACEUTICALS LTD LANSOPRAZOLE DELAYED-RELEASE CAP USP 30LANSOPRAZOLE DELAYED RELEASE CAPSULES USZAPACID 30 MG CAPSULE(LANSOPRAZOLE 30 MG | $14.9M | 7 | 5.1% |
| 5 | CIPLA LIMITED PYLOCARE KITS LANSOPRAZOLE CAPSULES & CLLANSOPRAZOLE MYLAN 30 MG 28BLLANZOL 30 CAPSULES ( | $11.3M | 9 | 3.9% |
| 6 | CAPLIN POINT LABORATORIES LIMITED LANSOPRAZOLE MYLAN 30 MG 28BLLANSOPRAZOLE ODT BIOGARAN 30MG 28 FRANCELANSOPRAZOLE ODT BIOGARAN 15MG 28 FRANCE | $9.5M | 7 | 3.3% |
| 7 | ZYDUS LIFESCIENCES LIMITED LANSOPRAZOLE DR OD TAB 30 MG - 10 X 10LANSOPRAZOLE MYLAN 30 MG 28BLLANSOPRAZOLE DR OD TAB 15 MG - 10 X 10TBS | $6.3M | 3 | 2.2% |
| 8 | DR.REDDY'S LABORATORIES LTD LANSOPRAZOLE DR OD TAB 30 MG - 10 X 10LANSOPRAZOLE DR OD TAB 15 MG - 10 X 10TBS | $5.2M | 3 | 1.8% |
| 9 | HETERO LABS LIMITED LANSOPRAZOLE DR OD TAB 30 MG - 10 X 10LANSOPRAZOLE DR OD TAB 15 MG - 10 X 10TBSLANSOLOC 30MG CAPS ( | $4.6M | 10 | 1.6% |
| 10 | MICRO LABS LIMITED LANSOPRAZOLE DELAYED-RELEASE CAP USP 30PYLOCARE KITS LANSOPRAZOLE CAPSULES & CLLANSOPRAZOLE DELAYED RELEASE CAPSULES US | $3.7M | 16 | 1.3% |
| 11 | AFROWAY PHARMA PYLOCARE KITS LANSOPRAZOLE CAPSULES & CL | $3.4M | 1 | 1.2% |
| 12 | ALKEM LABORATORIES LIMITED LANSOPRAZOLE DR OD TAB 30 MG - 10 X 10LANSOPRAZOLE DR OD TAB 15 MG - 10 X 10TBS | $2.4M | 2 | 0.8% |
| 13 | INVENTIA HEALTHCARE LIMITED LANSOPRAZOLE DR OD TAB 30 MG - 10 X 10LANSOPRAZOLE DR OD TAB 15 MG - 10 X 10TBS | $1.9M | 2 | 0.6% |
| 14 | COMBITIC GLOBAL CAPLET PRIVATE LIMITED DOMPERIDONE 10 MG AND LANSOPRAZOLE 30 MG | $1.5M | 2 | 0.5% |
| 15 | SUN PHARMACEUTICAL INDUSTRIES LIMITED LANSOLOC 30MG CAPS (RAN-LANSOPRAZOLE CAP 30MG PACK:4X7S BATCLANSOLOC OTC 15MG CAPSULES [109440X2X7'S] | $1.5M | 3 | 0.5% |
Related Analysis
Supplier Certification & Compliance Matrix
FDA, WHO-GMP, and EU GMP status for top Lansoprazole exporters
| Supplier | US FDA | WHO-GMP | EU GMP | ANDAs | Notes |
|---|---|---|---|---|---|
| MYLAN LABORATORIES LIMITED | Warning Letter issued Dec | Yes, as of March 202 | Unknown | Not verified | FDA issued a Warning Letter in December 2024 for the Indore facility; WHO conduc |
| LINCOLN PHARMACEUTICALS LTD | Not Listed | Yes, since 1984 | Yes, as of May | Not verified | Received EU GMP certification for the Khatraj facility in May 2020; WHO-GMP cert |
| CIPLA LIMITED | Approved | Yes | Yes | Not verified | Cipla has received approvals from FDA, WHO, and EU GMP for various facilities. |
| ZYDUS LIFESCIENCES LIMITED | Approved | Yes | Yes | Not verified | Zydus has received approvals from FDA, WHO, and EU GMP for various facilities. |
| DR. REDDY'S LABORATORIES LTD | Approved | Yes | Yes | Not verified | Dr. Reddy's has received approvals from FDA, WHO, and EU GMP for various facilit |
| MICRO LABS LIMITED | Approved | Yes | Yes | Not verified | Micro Labs has received approvals from FDA, WHO, and EU GMP for various faciliti |
| SUN PHARMACEUTICAL INDUSTRIES LIMITED | Approved | Yes | Yes | Not verified | Sun Pharma has received approvals from FDA, WHO, and EU GMP for various faciliti |
| ALKEM LABORATORIES LIMITED | Approved | Yes | Yes | Not verified | Alkem has received approvals from FDA, WHO, and EU GMP for various facilities. |
TransData Nexus reviewed the regulatory standing of 8 leading Lansoprazole exporters from India. 6 hold US FDA facility approvals, 8 maintain WHO-GMP certification, and 7 are EU GMP compliant. 1 supplier has received FDA regulatory actions — buyers should verify current remediation status before placing orders. For regulated markets (US, EU, Australia), prioritise suppliers with active FDA or EU GMP approvals. For semi-regulated markets (Africa, ASEAN, Latin America), WHO-GMP certification is the minimum recommended standard.
Certification status compiled from publicly available regulatory databases including FDA Orange Book, WHO Prequalification database, and EMA GMP registry. Buyers should independently verify compliance status with the relevant regulatory authority before placing orders.
TransData Nexus Research · Mar 2026
Manufacturing Hub Analysis — Vendor Proximity
India's pharmaceutical clusters relevant to Lansoprazole sourcing
1Hyderabad — Bulk Drug Capital
Hyderabad, often referred to as the "Bulk Drug Capital of India," is renowned for its extensive production of active pharmaceutical ingredients (APIs). The city's pharmaceutical ecosystem is bolstered by the presence of numerous API manufacturers and research institutions, making it a pivotal hub for the initial stages of drug synthesis. Companies like Sandoz Private Limited have established research and development centers in Hyderabad, contributing to the city's prominence in API production.
2Ahmedabad-Vadodara — Formulations Hub
The Ahmedabad-Vadodara corridor in Gujarat is a significant center for pharmaceutical formulations. This region hosts a multitude of companies specializing in the development and manufacturing of finished dosage forms, including tablets and capsules. Intas Pharmaceuticals, headquartered in Ahmedabad, exemplifies the region's strength in formulations, producing a wide range of generic therapeutic drugs.
3Mumbai-Thane-Raigad — Export Gateway
The Mumbai-Thane-Raigad belt serves as a crucial export gateway for pharmaceutical products. With its strategic coastal location and well-developed port infrastructure, this region facilitates the efficient export of pharmaceuticals to global markets. Sandoz Private Limited operates manufacturing facilities in Navi Mumbai, leveraging the area's logistical advantages to distribute products like Lansoprazole internationally.
4Baddi-Nalagarh — Tax Incentive Zone
Baddi-Nalagarh in Himachal Pradesh has emerged as a prominent pharmaceutical manufacturing zone, primarily due to favorable tax incentives offered by the government. These incentives have attracted numerous pharmaceutical companies to set up manufacturing units in the region, enhancing its production capacity for various drugs, including Lansoprazole.
5Sourcing Recommendations
- Diversify Supplier Base: Engage with multiple suppliers across different clusters to mitigate risks associated with regional disruptions.
- Evaluate Supplier Capabilities: Assess the technical expertise and compliance records of suppliers, especially those in Hyderabad for API sourcing and Ahmedabad-Vadodara for formulations.
- Leverage Export Infrastructure: Utilize the logistical advantages of the Mumbai-Thane-Raigad region to streamline international distribution channels.
- Consider Cost Benefits: Explore manufacturing options in the Baddi-Nalagarh zone to capitalize on tax incentives and potentially reduce production costs.
By strategically sourcing Lansoprazole from these specialized clusters, companies can optimize their supply chain, ensuring quality, cost-effectiveness, and reliability.
Recent M&A, Collaborations & Capacity Expansions
Industry developments among top Lansoprazole exporters from India
Cipla Limited — Cipla acquires Ivia Beaute's cosmetics and personal care business
Cipla Limited acquired Ivia Beaute Pvt Ltd's cosmetics and personal care distribution and marketing business for ₹130 crore. - IMPACT: This acquisition is not expected to directly impact Cipla's Lansoprazole export operations.
Impact: This acquisition is not expected to directly impact Cipla's Lansoprazole export operations.
Common Questions — Lansoprazole Suppliers from India
Answers based on Indian Customs (DGFT) shipment records compiled by TransData Nexus
Q Which lansoprazole supplier from India is the most reliable for bulk orders?
Based on shipment frequency and export consistency, SANDOZ PRIVATE LIMITED leads with 69 recorded shipments worth $159.0M. MYLAN LABORATORIES LIMITED (416 shipments) and PAR FORMULATIONS PRIVATE LIMITED (95 shipments) are also established high-volume exporters.
Q How many lansoprazole manufacturers are there in India?
India has 316 active lansoprazole exporters with a combined export market of $290.2M across 4,867 shipments to 105 countries. The top 5 suppliers hold 79.8% of total export value.
Q What certifications should I verify?
Verify: WHO-GMP certification (most markets), US FDA approval (United States), EU GMP certificate (EU/EEA), and Free Sale Certificate from CDSCO. Always request a Certificate of Analysis (CoA) and Certificate of Origin (CoO).
Q What is the typical price range for lansoprazole from India?
Average FOB unit price: $15.78 per unit, ranging from $0.01 to $2380.38. Average shipment value: $59.6K.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Supplier Ranking: 316 verified Indian exporters of Lansoprazole ranked by capped export value from DGFT shipping bill records.
- 2.Export Value Analysis: Total export value aggregated from 4,867 individual shipping bill records. Values are FOB in USD.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation.
- 4.Market Concentration: Supplier market share and geographic reach analyzed across 105 destination countries.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
4,867 Verified Shipments
316 exporters tracked
Expert-Reviewed
By pharmaceutical trade specialists